XERSHealthcare · BiotechnologyThe 7 Wall Street analysts covering Xeris Biopharma Holdings, Inc. hold a median 12-month price target of $10 — +16.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Xeris Biopharma Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (98): The business earns solid, repeatable profits on what it owns.
Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on XERS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +16.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 2 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
| 7 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2025 | Oppenheimer | Maintains | Outperform | — |
| 7 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
| 29 Oct 2025 | Oppenheimer | Maintains | Outperform | — |
| 17 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Aug 2025 | Leerink Partners | Maintains | Outperform | — |
| 12 Aug 2025 | HC Wainwright & Co. | Assumes | Buy | $10 |
| 8 Aug 2025 | Craig-Hallum | Maintains | Buy | — |
| 8 Aug 2025 | Oppenheimer | Maintains | Outperform | — |
| 5 June 2025 | Leerink Partners | Maintains | Outperform | — |
| 9 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 7 Mar 2025 | Craig-Hallum | Maintains | Buy | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | Leerink Partners | Maintains | Outperform | — |
| 7 Mar 2025 | Piper Sandler | Reiterates | Neutral | — |
| 29 Jan 2025 | Jefferies | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XERS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 6% of US stocks
Cheaper than 27% of US stocks
Cheaper than 1% of US stocks
Cheaper than 8% of US stocks
Higher than 78% of US stocks
Higher than 66% of US stocks
Higher than 95% of US stocks
Higher than 56% of US stocks
Higher than 24% of US stocks
Higher than 52% of US stocks
Higher than 82% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Xeris Biopharma Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Xeris Biopharma reported second-quarter total revenue of $92.1 million, up 29% year over year, with net product revenue rising 34% to $91 million. The company also raised the low end of its full-year 2026 revenue outlook to a range of $385 million to $390 million.
Why it matters — The strong quarterly revenue growth and upward revision to the full-year guidance signal improving commercial performance for Xeris watchers.
Seeking Alpha published the transcript of Xeris Biopharma Holdings, Inc.'s Q2 2026 earnings call. The item is the earnings call transcript for the company's second quarter of 2026.
Why it matters — A XERS watcher would care because the Q2 2026 earnings call transcript provides direct company commentary on its quarterly financial and operational results.
Zacks Investment Research examines Xeris Biopharma's Q2 (quarter ended June 2026) headline earnings figures, noting that it may be worthwhile to compare some of the company's key metrics against Wall Street estimates and year-ago actuals.
Why it matters — XERS watchers would care because comparing key Q2 metrics to analyst estimates and prior-year results offers insight into how the company actually performed in the quarter.
Xeris Biopharma reported its second quarter 2026 financial results, highlighting a 34% year-over-year increase in net product revenue driven by strong commercial momentum for Recorlev.
Why it matters — The 34% revenue growth and positive commentary on Recorlev's performance indicate accelerating commercial traction for one of Xeris's key products.
The 7 Wall Street analysts covering Xeris Biopharma Holdings, Inc. have a median 12-month price target of $10, with estimates ranging from $8 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Xeris Biopharma Holdings, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xeris Biopharma Holdings, Inc. 85 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Xeris Biopharma Holdings, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +16.3% from the last close, and Ticker Nerd's factor model ranks Xeris Biopharma Holdings, Inc. 85 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Xeris Biopharma Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XERS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $18 over the next 12 months.
Xeris Biopharma Holdings, Inc. returned +17.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company headquartered in Chicago, Illinois.
The most recent item we track (MarketBeat, 7 Aug 2026): "Xeris Biopharma Q2 Earnings Call Highlights". Xeris Biopharma reported second-quarter total revenue of $92.1 million, up 29% year over year, with net product revenue rising 34% to $91 million. The company also raised the low end of its full-year 2026 revenue outlook to a range of $385 million to $390 million.
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company headquartered in Chicago, Illinois. It specializes in developing and commercializing therapies for chronic endocrine and neurological conditions, with a commercial portfolio featuring three key products: Recorlev for treating endogenous Cushing's syndrome in adults unsuitable for surgery, Gvoke for severe hypoglycemia, and Keveyis for Primary Periodic Paralysis. The company leverages proprietary XeriSol and XeriJect formulation platforms to enable innovative subcutaneous and ready-to-use injectable delivery systems, including the recent commercial launch of Gvoke VialDx, a concentrated liquid glucagon for diagnostic use in radiologic procedures via a partnership with American Regent. Xeris Biopharma Holdings, Inc. maintains an active pipeline, highlighted by XP-8121, a novel levothyroxine formulation for potential endocrine applications, supported by recent U.S. patent allowances. These efforts position the company as a focused player in rare disease treatments within the biotechnology sector, emphasizing patient access, intellectual property protection, and commercial expansion in the U.S. market.
CEO Mr. John P. Shannon · 394 employees · United States · https://www.xerispharma.com